Although systemic lupus erythematosus cannot be cured, there are a number of drugs available to help manage this chronic ...

This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no ...

Myasthenia gravis is an autoimmune disorder in which antibodies disrupt the communication between nerves and muscles, ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

Relapse is common, and long-term low-dose prednisone or azathioprine therapy is preferred ... and its actuarial 10-year survival rate is 75%. Drugs such as cyclosporine, tacrolimus, and ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

Discover how Mediterranean strawberry tree extract shows promise for treating ulcerative colitis with fewer side effects than drugs.

Study approach The TRINITY study was a prospective diagnostic accuracy trial conducted at the Asian Institute of ...

There were more than 48,000 organ transplants in the United States last year. They’re commonplace now, but the practice was considered experimental only a half-century ago.

The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...